
Opinion|Videos|April 6, 2026
Rethinking High-Risk EGFR-Mutant NSCLC
Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, examine how high-risk disease is defined and applied in clinical practice.
Advertisement
Episodes in this series

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, discuss the evolving definition of high-risk EGFR-mutant NSCLC, including factors such as brain and liver metastases, TP53 co-mutations, circulating tumor DNA status, and overall disease burden. They explore whether molecular complexity is becoming a stronger driver of treatment intensification than clinical features alone, and caution against over-interpreting co-mutations without prospective validation.
Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
5

